Treatment A (BDA MDI HFO) + Treatment B (BDA MDI HFA)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Heathy Participants
Conditions
Heathy Participants
Trial Timeline
Nov 16, 2023 → May 4, 2024
NCT ID
NCT06139991About Treatment A (BDA MDI HFO) + Treatment B (BDA MDI HFA)
Treatment A (BDA MDI HFO) + Treatment B (BDA MDI HFA) is a phase 1 stage product being developed by AstraZeneca for Heathy Participants. The current trial status is completed. This product is registered under clinical trial identifier NCT06139991. Target conditions include Heathy Participants.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06139991 | Phase 1 | Completed |
Competing Products
4 competing products in Heathy Participants
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD7053 + Placebo | AstraZeneca | Phase 1 | 33 |
| Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube | AstraZeneca | Phase 1 | 33 |
| PF-06700841 + Itraconazole | Pfizer | Phase 1 | 32 |
| Immune Globulin (Human) | Grifols | Approved | 82 |